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Abstract
BACKGROUND: Claudin-4, a tight junction (TJ) protein
and receptor for the C-terminal fragment of Clos-
tridium perfringens enterotoxin (C-CPE), is overex-
pressed in epithelial ovarian cancer (EOC). Previous
research suggests DNA methylation is a mechanism
for claudin-4 overexpression in cancer and that C-CPE
acts as an absorption-enhancing agent in claudin-4–
expressing cells. We sought to correlate claudin-4
overexpression in EOC with clinical outcomes and
TJ barrier function, investigate DNA methylation as a
mechanism for overexpression, and evaluate the effect
of C-CPE on the TJ. METHODS: Claudin-4 expression
in EOC was quantified and correlated with clinical out-
comes. Claudin-4 methylation status was determined,
and claudin-4–negative cell lines were treated with
a demethylating agent. Electric cell–substrate imped-
ance sensing was used to calculate junctional (para-
cellular) resistance (Rb) in EOC cells after claudin-4
silencing and after C-CPE treatment.RESULTS:Claudin-
4 overexpression in EOC does not correlate with sur-
vival or other clinical endpoints and is associated with
hypomethylation. Claudin-4 overexpression correlates
with Rb and C-CPE treatment of EOC cells significantly
decreased Rb in a dose- and claudin-4–dependent non-
cytotoxic manner. CONCLUSIONS: C-CPE treatment of
EOC cells leads to altered TJ function. Further research
is needed to determine the potential clinical applications
of C-CPE in EOC drug delivery strategies.
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Introduction
Gene expression profiling has led to the discovery of novel
genes and pathways thought to be important in ovarian cancer
tumorigenesis [1]. One such gene identified by our group [2]
and others [3–7] is claudin-4 (CLDN4). The claudins are a
group of over 20 proteins that are expressed in a tissue-specific
manner and form the backbone of tight junction (TJ) strands
[8,9]. Tight junctions play an important role in the maintenance
of cell polarity and the regulation of paracellular transport.
Through their homophilic and heterophilic interactions, clau-
dins help to define the ability of TJs to affect the strength and
selectivity of paracellular resistance [10]. Furthermore, recent
evidence suggests that claudins play a role in a wide variety of
cellular signaling processes through their cytosolic carboxy-
terminal interaction with PDZ-containing proteins such as ZO-1
[8,9]. As such, evidence is mounting to suggest that cell
adhesion molecules in general [11], and TJs and claudins
specifically, influence a wide variety of processes including cell
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signaling, proliferation, differentiation, trafficking, and po-
larity, and may thus play an important role in the coordinated
molecular biochemistry of the tumor microenvironment [9].
Recent studies have implicated alterations of a number of
claudin isotypes in malignancy [12]. Claudin-7 was shown to
be underexpressed in ductal carcinomas of the breast [13],
whereas claudin-3 is overexpressed in prostate, breast, and
ovarian cancers [6,14,15]. These changes have been noted
in preinvasive carcinomas [13,16], and in some cases, can
be correlated with tumor grade and subtype [13]. In addi-
tion to ovarian cancer, claudin-4 has been found to be ele-
vated in prostate, pancreatic, gastric, and breast cancers
[14,15,17,18]. Interestingly, the role of claudin-4 in each of
these tissue types appears to be variable. In pancreatic
cancer, claudin-4 overexpression leads to decreased inva-
siveness and metastatic potential while having no effect on
proliferation, cell cycle, or matrix metalloproteinase activity
[17]. In contrast, claudin-3 and claudin-4 expression have
been associated with increased invasiveness and metallo-
proteinase-2 activity in ovarian cancer [19]. Although the
mechanism of claudin-4 overexpression has yet to be fully
elucidated [20], recent studies have shown that the methyla-
tion status of claudins appears to be important. Decreased
expression of claudin-7 in breast cancer has been as-
sociated with promoter hypermethylation, whereas CLDN4
hypomethylation has been associated with overexpression
in pancreatic cancer [21].
Several investigators have sought to exploit the thera-
peutic potential of claudin-4 overexpression in a variety of
cancers. Both in vitro and animal studies in breast, prostate,
and ovarian cancers have shown that Clostridium perfrin-
gens enterotoxin (CPE), which binds to claudin-4, may have
an important therapeutic benefit, as it is rapidly cytotoxic in
tissues overexpressing claudin-4 [7,14,15,17]. The recent
report by Santin et al. [7] showing the successful treatment of
epithelial ovarian cancer (EOC) with intraperitoneal (IP) CPE
in SCID mice is promising; however, claudin-4 is expressed
in a number of normal tissues [15], and some authors have
suggested that IP CPE may have potentially significant toxic
side effects [14,22]. However, the noncytotoxic receptor-
binding C-terminus of CPE (C-CPE) can disrupt TJs and
has been shown to be an absorption-enhancing agent in
epithelia [23,24]. The use of IP ‘‘chemosensitizers’’ that can
decrease tumor density and improve drug penetration (by
surface diffusion) [25] may be an attractive method of
improving cytotoxic drug delivery, given the important role
of adjuvant IP chemotherapy in advanced EOC [26], Alter-
natively, tumor-specific drug delivery may be improved by
using C-CPE as a claudin-4 targeting molecule by fusing it
to cytotoxic drugs directly [27].
Our previously described oligonucleotide array [2] sug-
gested that CLDN4 was one of the most highly overex-
pressed genes in ovarian cancer. We sought to validate the
overexpression of claudin-4 in EOC and to correlate ex-
pression with several clinical outcomes. We also sought to
investigate the possibility that the methylation status of
CLDN4 contributes to its overexpression in ovarian cancer.
Lastly, we explored the relationship between claudin-4 over-
expression and junctional (paracellular) resistance, a mea-
sure of TJ ‘‘barrier function,’’ and examined the ability of
C-CPE to act as a nontoxic modulator of junctional resis-
tance in ovarian cancer cell lines.
Materials and Methods
Tissue Samples
Paraffin-embedded tissue was collected and archived
from patients undergoing surgery at Brigham and Women’s
Hospital (Boston, MA). All patient-derived specimens were
collected under protocols approved by the institutional re-
view board. Clinical stage, as defined by the International
Federation of Gynecology and Obstetrics system, was de-
termined by chart review, and histologic subtype and grade
were assigned by pathologists according to World Health
Organization guidelines.
Cell Lines
A total of 20 ovarian cancer cell lines were used, and
included cell lines derived from serous (ALST, CAOV3,
DOV13, OVCAR3, OVCA420, OVCA429, OVCA432,
OVCA433, OVCA633, PEO4, REST, SKOV3, 2008), mucin-
ous (MCAS, RMUG-L, RMUG-S), clear cell (ES2, TOV21G,
RMG1), and endometrioid adenocarcinomas (TOV112D).
Cell lines SKOV3, RMG1, ES2, OVCAR3, MCAS, RMUG-L,
RMUG-S, and TOV112D were purchased from American
Type Culture Collection (Rockville, MD) or from the Japa-
nese Collection of Research Bioresources (Tokyo, Japan),
and 2008 was obtained from The University of Texas South-
western Medical Center (Dallas, TX). The remaining cell
lines were established in our laboratory. Normal human
ovarian surface epithelium (HOSE) cells were obtained from
fresh ovarian scrapings at the time of surgery for benign non-
ovarian conditions. Immortalized HOSE cells were obtained
by HPVE6E7 immortalization of normal HOSE cells [28].
Cells were maintained at 37jC in a 5% carbon dioxide
incubator and were cultured in a filter-sterilized medium
consisting of equal parts M199 (Sigma, St. Louis, MO) and
MCDB105 (Sigma), supplemented with 10% fetal bovine
serum and L-glutamine–penicillin–streptomycin (10 ml/L,
Sigma). Cell culture medium was changed every 1 to 2 days,
depending on the rate of cell growth, and cells were sub-
cultured at 80% confluence using 1 trypsin solution.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted, purified, and quantified from
laser microdissected tissue samples or cell lines and then
converted to cDNA as described previously [2,29]. Quan-
titative real-time polymerase chain reaction (qRT-PCR)
was performed by use of the 7300 Real-Time PCR Sys-
tem. TaqMan Gene Expression Assay probes for cyclo-
philin A (an endogenous control) and claudin-4 (assay ID
Hs00533616_s1, assay location 1484, reference sequence
NM_001305.3) were purchased from Applied Biosystems
(Foster City, CA). For each qRT-PCR reaction, claudin-4
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and cyclophilin A were multiplexed as follows: 2 ml of cDNA
was added to 10 ml of TaqMan Universal PCR Master Mix
(Applied Biosystems), 1 ml of claudin-4 TaqMan primer/
probe, 1 ml of cyclophilin A TaqMan primer/probe, and
6 ml of autoclaved distilled water. Reactions started with a
10-minute hold at 95jC, followed by 40 cycles of denatur-
ation at 95jC for 125 seconds, followed by annealing/
extending at 60jC for 1 minute. All experiments were run
in duplicate (values averaged) and repeated at least twice.
The 7300 Real-Time PCR System software monitored the
amplification process and determined the threshold cycle
(Ct) for each reaction. Quantification (fold-change calcula-
tion) was relative to a HOSE sample and was determined
by the DDCt method as described previously [30].
Immunohistochemistry
Paraffin-embedded tissue samples were cut to 7-mm sec-
tions and mounted on Superfrost Plus microscope slides
(Fisher Scientific, Pittsburgh, PA). Deparaffinization and anti-
gen retrieval were performed by using BORG Decloaker
(Biocare Medical, Walnut Creek, CA) solution and the
Decloaking Chamber 2002 (Biocare Medical) electric pres-
sure cooker. Slides were sequentially washed with 1 Hot
Rinse (Biocare Medical), deionized water, and 1 TBS, then
incubated with mouse anti–claudin-4 antibody (Zymed Labo-
ratories Inc., South San Francisco, CA) at 1:50 dilution (in
1 TBS) for 60 minutes in a moist chamber at room tempera-
ture. Immunohistochemistry (IHC) was performed by using
the EnVision-AP system (DakoCytomation, Carpinteria, CA)
according to the manufacturer’s recommendations. Slides
were washed with deionized water, counterstained with
hematoxylin and 5% ammonium hydroxide, and mounted in
Accergel (Accurate Chemical and Scientific Corp., Westbury,
NY). Control slides (incubated in 1 TBS without anti–
claudin-4 antibody) were similarly prepared.
Western Blot
For the isolation of protein lysates, cells were first washed
twice with 1 PBS, then lysed with a solution of RIPA Buffer-2
(Boston BioProducts, Worcester, MA), PMSF (Sigma), and
Protease Inhibitor Cocktail (Sigma). After briefly vortexing
and centrifuging at 4jC, the Micro BCA Protein Assay Kit
(Pierce Chemical Co., Rockford, IL) was used for protein
quantification of the cell lysates. Total cell lysates were re-
solved using a 1-D 10% SDS-PAGE gel (25 mg per sample).
The resolved proteins were transferred to a (polyvinylidene
fluoride) membrane (Perkin Elmer, Boston, MA) using the
SEMI-DRY Transfer Cell (Bio-Rad Laboratories, Hercules,
CA). After transfer, the PVDF membrane was washed and
blocked with 5% nonfat dry milk at 4jC overnight. The mem-
brane was subsequently incubated in anti–claudin-4 (Zymed)
antibody in blocking solution at 1:2500 dilution for 1 hour, after
which it was washed and incubated with antimouse IgG
secondary antibody (1:2500) for 1 hour. For signal detection,
the membrane was incubated with SuperSignal West Pico
Chemiluminescent Substrate (Pierce) for 5 minutes, after
which the membrane was exposed to film and the film was
developed. To normalize for protein loading and transfer,
b-actin was used as a positive control (1:50,000, Sigma).
Western blot was performed on 13 ovarian cancer and
3 HOSE cell lines and blot intensity was quantified by using
computer imaging software (Bio-Rad). Blot intensity was
normalized to b-actin expression and correlated to claudin-4
expression as determined by qRT-PCR.
Methylation-Specific PCR and Bisulfite Sequencing
CpG Island Searcher software (http://ccnt.hsc.usc.edu/
cpgislands/) was used to identify a CLDN4 CpG island using
the following criteria: %GC = 55, ObsCpG/ExpCpG = 0.65,
length of CpG island, z500 bp, distance between islands,
z100 bp. Methylation-specific PCR (MSPCR) was per-
formed using the CpGenome DNA Modification Kit (Chem-
icon International, Temecula, CA) [31]. Genomic DNA was
extracted and purified from cell lines and tissue samples as
described previously [32]. Bisulfite modification was per-
formed according to the manufacturer’s instructions. PCR
was then performed using primer sequences for methylated
reactions [5V-CTA CCG ATA AAA ACC GTC ACG-3V (for-
ward), 5V-GTG TAT TTT GCG AAC GTT AAG TTC-3V (re-
verse)] and unmethylated reactions [5V-AAT ATT ACT ACC
AAT AAA AAC CAT CAC AC-3V (forward), 5V-TGT ATT TTG
TGA ATG TTA AGT TTG T-3V (reverse)] (Sigma-Genosys,
The Woodlands, TX). The PCR mixture contained 1 PCR
Gold Buffer, 5 mmol/l MgCl2, 2 ml dNTP 10 mmol/l, 1 ml each
of forward and reverse primers, 0.125 ml AmpliTaq Gold,
and 2 ml of DNA and brought to a total volume of 25 ml
by addition of autoclaved deionized water (all reagents
from Applied Biosystems). PCR reactions were hot started
at 94jC for 12 minutes, followed by 35 cycles (30 sec-
onds at 94jC, 30 seconds at the annealing temperature,
30 seconds at 72jC) and a final 7-minute hold at 72jC.
Different annealing temperatures (57jC, 54jC) were used
to account for the different melting temperatures of the
methylated and unmethylated primers, respectively. Each
PCR product was loaded into a 1% agarose or 10% acryl-
amide gel, stained with ethidium bromide, and visualized
under UV illumination. Nine ovarian cancer tissue samples,
11 ovarian cancer cell lines, and 3 HOSE cell lines under-
went MSPCR, and the CLDN4 methylation status was com-
pared to its expression. On average, MSPCR was repeated
three to four times for each cell line. MSPCR was also per-
formed on unmodified genomic DNA, as a negative con-
trol, and on methylated control DNA (Universal Methylated
DNA, Chemicon).
Bisulfite-modified DNA was prepared for bisulfite se-
quencing to assess for the completeness of the bisulfite
treatment and the accuracy of the MSPCR results. The
OVCA429 ovarian cancer cell line, which demonstrated
a hypomethylated CLDN4 allele only, was used for this
purpose. PCR amplification was performed on 100 ng of
bisulfite-modified genomic DNA and the product was used
for sequencing. The PCR primers used were 5V-TTG GAA
GGA ATT GGT TTG TTT ATA T-3V (forward) and 5V-CAT
AAA CCC TCC CAA ATA ATC TAC-3V (reverse); the an-
nealing temperature was 57jC. The amplification product
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was cloned and sequenced; 21 CpG dinucleotides sites
were located within the PCR product.
To assess the effect of DNA methylation, cell lines DOV13
and TOV112D (neither of which expressed claudin-4) were
treated with 1 mmol/l 5-AZA-2V-deoxycytidine (5-AZA, Sigma),
an inhibitor of DNA methylation. Treatment of cell cultures
started at 30% to 40% confluence for a total of four days. The
medium and drug were changed every 24 hours and the cell
cultures were confluent for at least 48 hours before collec-
tion. MSPCR and qRT-PCR was then performed, in dupli-
cate, as described above.
Preparation and Cell Culture with C-CPE
The C-terminal fragment of CPE (C-CPE) was attained
using a 3V fragment of the cpe gene cloned into the pTrcHis B
expression vector, as described previously [33]. Sonic
lysates from Escherichia coli transformants expressing
C-CPE were filtered with a MILLEXHV 0.45-mm PVDF Filter
(Millipore, Billerica, MA) and then applied to a HiTrap metal
chelating column (Amersham Biosciences, Piscataway,
NJ) preequilibrated with HiTrap Binding Buffer (20 mmol/l
NaH2PO4, 500 mmol/l NaCl, 60 mmol/l imidazole, pH 7.4).
C-CPE was eluted from the column with an imidazole
gradient, and C-CPE containing fractions were pooled and
dialyzed against distilled water (pH 7.0). The amount of
C-CPE recovered from the purifications was estimated by
the Lowry method, and the final enriched C-CPE product
(90–95% purity) was stored frozen at 80jC until use.
C-CPE was thawed at 4jC and serially diluted in cell cul-
ture medium, after which it was immediately used in experi-
ments. The Micro BCA Protein Assay Kit (Pierce) was used
to determine protein concentrations. The effect of C-CPE
on cell viability was assessed by the CellTiter-Blue Cell Via-
bility Assay (Promega Corp., Madison, WI). The OVCA429
ovarian cancer cell line, one of the highest overexpressers
of claudin-4, was subcultured on 96-well black-walled/
clear-bottomed plates (BD Biosciences, Franklin Lakes,
NJ) at 1  104 cells per well and incubated overnight at
37jC before treatment. Subsequently, the cell culture me-
dium was changed and medium containing C-CPE was
added, after which the cells were incubated for 44 to
48 hours at 37jC. Cell morphology was visually inspected,
after which the Spectra Max Gemini (Molecular Devices Co.,
Sunnyvale, CA) microplate spectrofluorometer was used
for cell viability measurements. Each set of experiments
contained wells to control for background fluorescence.
Electric Cell–Substrate Impedance Sensing Measurements
The electric cell–substrate impedance sensing (ECIS)
system was used to measure transepithelial impedance in
ovarian cancer cell lines alone and after exposure to C-CPE.
Transepithelial impedance measurements were used to cal-
culate the junctional resistance Rb, a measure of TJ barrier
function and paracellular resistance, by data fitting and
model analysis, as briefly described below [34,35]. First,
transepithelial impedance was measured in nine ovarian
cancer cell lines during 5 days of exposure to cell culture
medium alone. These cell lines all overexpressed claudin-4,
albeit at varying levels: low (TOV112D, RMUG-L, ES2,
SKOV3), higher (OVCAR3, RMUG-S, CAOV3), and highest
(OVCA429, RMG1). The parameter Rb was calculated by
using ECIS, after which it was statistically correlated to the
level of claudin-4 overexpression (as assessed by qRT-
PCR). To further demonstrate the relationship between
claudin-4 expression and Rb, transepithelial impedance
was measured during 7 days of cell culture and Rb was
calculated and compared in the wild-type and small inter-
fering RNA (siRNA) claudin-4 silenced SKOV3 cell lines.
ECIS measurements were also obtained in ovarian cell
lines OVCA429 and SKOV3 during drug treatment with
increasing doses of C-CPE. C-CPE was added to the apical
aspect of cells in culture and dose–response plots were
generated based on the dynamic response of the parameter
Rb 60 hours after exposure to C-CPE.
Claudin-4 silencing was performed by introducing a ho-
mologous double-stranded RNA into the ovarian cancer cell
line, SKOV-3. SKOV-3 cells (2  105) were cultured in T25
flasks, after which they were transfected with claudin-4
siRNA duplex (Silencer Predesigned siRNA) or control
RNA duplex (Silencer Negative Control) using the siRNA
transfection kit (Silencer siRNA Transfection II) according to
the manufacturer’s instructions (all products from Ambion,
Austin, TX). Cells were treated for 48 hours in the transfec-
tion reagent to allow for maximum claudin-4 silencing, after
which they were placed in cell culture medium and used
for ECIS experiments within 24 hours. A Western blot was
performed to confirm claudin-4 silencing.
For ECIS measurements, 9  104 cells were plated
into each well (1 cm in height, 0.9 cm2 in area) of an elec-
trode array. Each electrode array consisted of eight wells;
0.4 ml of medium was used per well. Cell density was
controlled at 1  105 cells/cm2. After 48 hours in culture,
the confluence and viability of the cell monolayer were
confirmed by light microscopy and electrically. The experi-
mental conditions were then imposed and transepithelial
impedance data were obtained from cell-covered electrode
arrays. The electrode arrays, lock-in amplifier, and soft-
ware for the ECIS were obtained from Applied Biophysics
(Troy, NY). Attached cells on the electrode will act as
insulating particles; accordingly, current will flow through
cell–substrate spaces beneath the cell that can eventually
lead to the paracellular space. Changes in cell morphology
manifest as changes in impedance as the paracellular
and/or cell –substrate spaces changes, and the contri-
bution of each of these is accounted for separately in
the ECIS system model. We applied a 1-V AC signal at
4000 Hz to the samples through a 1-mV resistor and moni-
tored transepithelial impedance changes. The current of
1 mA across the cell layer had no detectable deleterious
effect on the cells. The impedance of each well was mea-
sured at 2-minute intervals; impedance for both a cell-free
and a cell-covered electrode was measured at frequencies
from 25 to 60 kHz. Comparing the experimental data from
cell-covered electrodes with the calculated values obtained
from the model and the impedance data from the cell-free
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electrode, we determined the parameter Rb as described
previously [34,35].
Statistical Analysis
Survival data were collected by chart review and ar-
chived under protocols approved by the institutional review
board. qRT-PCR data were tested for normality by using the
Kolmogorov–Smirnov method and failed (P < .001); there-
fore, nonparametric methods (Mann–Whitney test, Kruskal–
Wallis, Spearman’s rank correlation) were used for sta-
tistical analysis. Using a subset of 56 grade 3, advanced-
stage (stages 3 or 4) samples, claudin-4 expression was
correlated with survival, chemosensitivity, optimal debulking
status, primary versus recurrent tumors, and short-term
versus long-term survival. ECIS data were tested for nor-
mality vy using the Kolmogorov–Smirnov method. One-
way analysis of variance and the Bonferroni t test were
used to compare the effect of various concentrations of
C-CPE on the parameter Rb. All statistical testing was
performed by using software provided by Statview (SAS,
Cary, NC), Minitab (State College, PA), or SigmaStat (Point
Richmond, CA), and statistical significance was defined
as a < .05.
Results
As shown in Figure 1A, significantly higher claudin-4 ex-
pression was found in borderline (n = 18, P = .003), low-
grade (n = 5, P = .02), and high-grade cancers (n = 56, P <
.001) when compared with HOSE (n = 4). However, there
was no difference in claudin-4 expression between border-
line, low-grade, and high-grade serous carcinomas (P =
.14, Figure 1B). IHC data are summarized in Figure 1 and
representative slides are shown in Figure 2. Claudin-4
staining intensity was generally strong in endometrioid car-
cinomas, strong to intermediate in high-grade serous, bor-
derline serous, and mucinous carcinomas, and weak in clear
cell carcinomas. Claudin-4 expression by qRT-PCR and IHC
were compared in a subset of 42 grade 3, advanced-stage
(stages 3 or 4) serous cancers and found to have a statis-
tically significant relationship (P = .04).
Claudin-4 expression was also found to be significantly
higher in ovarian cancer cell lines when compared to HOSE
(P < .001) and immortalized HOSE (P = .04) (Figure 3A).
Nine of 14 serous (TOV21G to 2008), two of three mucinous
(RMUGL to MCAS), and one of two clear cell (ES2, RMG1)
cancer cell lines exhibited greater than 100-fold increased
expression compared to HOSE. Similarly, Western blot
Figure 1. (A) qRT-PCR was used to compare claudin-4 expression in 79 serous ovarian cancer tissue samples of various grades to HOSE tissue. Claudin-4
expression was significantly higher in borderline, low-grade, and high-grade cancers when compared to HOSE. *P = .003, **P = .02, ***P < .001; (B) expression
was not significantly different between high-grade and borderline or low-grade cancers (P = .14). Table: Using IHC, 76 ovarian cancer tissue samples of various
histologic types were stained for claudin-4 and compared to nine HOSE and six endosalpingiosis samples. Slides were scored as follows: 0, absent/trace staining;
1, minimal staining; 2, moderate staining; 3, strong staining. Samples were categorized into ‘‘claudin-4–negative’’ (absent/trace staining, score 0) and ‘‘claudin-
4–positive’’ (any degree of staining, scores 1–3) groups for comparison and statistical analysis.
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(Figure 3B) showed claudin-4 expression in 8 of the 13
ovarian cancer cell lines, whereas expression was absent
in all three HOSE cell lines. In these ovarian cancer cell
lines, Western blot claudin-4 expression positively correlated
with qRT-PCR claudin-4 expression (R = 0.70, P = .01).
Claudin-4 expression was correlated to a number of
clinically important outcomes in a subset of high-grade,
advanced-stage serous ovarian cancer samples. Cox pro-
portional hazards testing did not reveal any significant asso-
ciation between claudin-4 expression and survival (P = .21).
Claudin-4–positive and claudin-4–negative IHC groups
were compared by using Kaplan–Meier methods (curves
not shown) and no difference in survival was found (log rank
test, P = .42). As depicted in Figure 3C, claudin-4 expression
was not different between paired primary and recurrent
tumors (n = 7, P = .11), platinum-sensitive and platinum-
resistant tumors (n = 36, P = .47), or short-term survivors
(less than 24 months) and long-term survivors (60 months or
more) (n = 35, P = .99). No statistically significant relationship
was found between claudin-4 expression (as assessed by
IHC) and optimal debulking (n = 42, Fisher exact test, P =
.71) or platinum chemosensitivity (n = 30, Fisher exact test,
P = .67). Twelve of the 18 borderline carcinomas were
clinically stage I, whereas almost all of the high-grade
carcinomas were stage III or IV. There was no difference in
claudin-4 expression based on stage in borderline carcino-
mas (analysis of variance, P = .99) or high-grade carcinomas
(Fisher exact test, P = .38).
The methylation status of CLDN4 was determined in nine
ovarian cancer tissue samples (Figure 4A), all of which
exhibited both methylated and unmethylated PCR products.
All nine of these samples overexpressed claudin-4 com-
pared to HOSE (qRT-PCR fold change f80–200, per
Figure 1A). Seven of the 11 ovarian cancer cell lines ex-
hibited an unmethylated CLDN4 allele, and each of these
expressed claudin-4. In contrast, in all four cancer cell lines
with a methylated allele only, claudin-4 expression was
absent. The three HOSE cell lines exhibited both methylated
and unmethylated PCR products—none of them expressed
claudin-4. DOV13 and TOV112D, neither of which expressed
claudin-4 (per Figure 3B) and both of which had a methylated
CLDN4 allele only, were treated with 5-AZA, an inhibitor of
DNA methylation. 5-AZA treatment increased claudin-4 ex-
pression, as demonstrated by qRT-PCR, and was accom-
panied by the appearance of a new unmethylated band on
MSPCR in both cell lines (Figure 5). To confirm the com-
pleteness of the bisulfite modification and the accuracy of
MSPCR, bisulfite sequencing was performed on OVCA429,
Figure 2. Representative claudin-4– immunostained IHC slides from various histologic types of ovarian tissue. (A) Normal ovarian surface epithelium, (B) endo-
salpingiosis, (C and D) borderline serous carcinoma, (E and F) high-grade serous carcinoma, (G) clear cell carcinoma, (H) endometrioid carcinoma, and (I)
mucinous carcinoma. Scale bar = 20 m.
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a cancer cell line with an unmethylated CLDN4 allele only
(per Figure 4 B). Figure 6A shows the location of the CpG
island and MSPCR and bisulfite-sequencing primers. The
bisulfite-sequenced fragment contained 21 CpG dinucleo
tides, all of which were unmethylated (Figure 6B).
Using ECIS, transepithelial impedance was measured
and junctional (paracellular) resistance Rb was calculated
in nine ovarian cancer cell lines with varying levels of claudin-
4 overexpression (qRT-PCR fold change range, 2–2120).
There was a positive correlation between Rb and claudin-4
(R = 0.85, P < .001). Using siRNA, claudin-4 expression
was silenced in the cancer cell line SKOV3 (Figure 7A) and
Rb was determined during 7 days in culture. As shown in
Figure 7B, Rb was lower in the claudin-4 silenced SKOV3
Figure 3. (A) qRT-PCR was used to compare claudin-4 expression in 20 ovarian cancer cell lines to eight HOSE and six immortalized HOSE cell lines. *P < .001,
**P = .04. (B) Claudin-4 expression, as determined by Western blot, in ovarian cancer and HOSE cell lines. -Actin was used as a loading control. (C) Claudin-4
expression, as determined by qRT-PCR, was compared in a subset of high-grade advanced-stage tissue samples. There was no statistically significant difference
between paired primary and recurrent tumors, platinum-sensitive and platinum-resistant tumors, or short-term (less than 24 months) and long-term (60 months or
more) survivors.
Figure 4.MSPCR was performed and average of three to four times on genomic DNA obtained from (A) nine claudin-4–expressing ovarian cancer tissue samples
(393, 358, 377, 317, 351, 345, 312, 380, 412), (B) 11 ovarian cancer cell lines (OVCAR3, OVCA429, OVCA433, DOV13, PEO4, ES2, CAOV3, TOV112D, MCAS,
RMUG-L, OVCA432) and three HOSE cell lines (HOSE2166, HOSE2170, HOSE2177). Also shown in (B), the methylation status of CLDN4 was compared to its
protein expression in the cell lines. -Actin was used as a loading control. Me, methylated primer; U-Me, unmethylated primer; WB, Western blot.
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compared with the wild-type SKOV3, and this was found to
be statistically significant on days 6 and 7. Exposure of
OVCA429 (highly claudin-4 overexpressing, per Figure 3A)
to increasing concentrations of C-CPE did not result in any
changes in cell morphology, nor did it result in cell cytotoxicity
(data not shown). However, in OVCA429, C-CPE treatment
resulted in a dose-dependent and statistically significant (P <
.05) f50% decrease in Rb (compared to a control concen-
tration of 0 mg/ml) after 60 hours at concentrations of 1103,
1  102, and 1  101 mg/ml (Figure 7C). In contrast, when
SKOV3 (lower claudin-4 overexpression) was treated with
C-CPE, it remained relatively resistant to changes in Rb,
except at the highest C-CPE concentration (1  101 mg/ml),
when a significant f40% decrease in Rb was observed
compared to control (Figure 7D).
Discussion
This study sought to elucidate the patterns, mechanism, and
significance of claudin-4 overexpression in EOC. Our results
show that claudin-4 is overexpressed in almost all border-
line and invasive serous ovarian carcinomas. Nonetheless,
claudin-4 expression is not different between grades and
stages and was absent in all the HOSE and endosalpin-
giosis samples. As some borderline carcinomas are thought
to progress in a stepwise fashion toward their malignant
counterparts [36], this raises the possibility that claudin-4
overexpression may be an early event in EOC tumorigene-
sis. Other investigators have come to similar conclusions,
noting aberrant claudin expression in preinvasive as well
Figure 5. Ovarian cancer cell lines DOV13 and TOV112D, neither of which
expressed claudin-4, were treated with 5-AZA (1 mol/l), an inhibitor of DNA
methylation. Treatment with 5-AZA resulted in the appearance of new
unmethylated MSPCR products (inset) and corresponded with increased
expression of claudin-4, as assessed by qRT-PCR (bar graph). The
experiments were performed in duplicate. Also shown, MSPCR resulted in
a methylated product for the methylated control DNA; PCR products were
absent for unmodified DNA (which had not undergone bisulfite treatment).
Me, methylated primer; U-Me, unmethylated primer.
Figure 6. (A) The schematic diagram represents claudin-4 mRNA: +1, transcription initiation site; j (vertical marks), CpG dinucleotide; blue band, CpG island
identified using CpG Island Searcher software (http://ccnt.hsc.usc.edu/cpgislands/) and the displayed criteria; a (arrowhead), forward (BSF, bp 156–180) and
reverse (BSR, bp 468–491) primer locations for the bisulfite sequencing; ! (arrows), forward (MSPF, bp 233–256) and reverse (MSPR, bp 432–452) primer
locations for MSPCR. (B) The ovarian cancer cell line OVCA429, which exhibited a hypomethylated CLDN4 allele only (per Figure 4B), underwent bisulfite
sequencing. Complete hypomethylation was demonstrated at all 21 CpG dinucleotides (circled and numbered) in the sequenced fragment.
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as invasive carcinomas of the pancreas, breast, and cervix
[13,16,37]. Our current findings expand on those of Rangel
et al. [6] and Zhu et al. [38], who reported on claudin-4
expression in various histologic subtypes of EOC, albeit in
small numbers. Interestingly, the highest percentage of
staining occurred in endometrioid and clear cell carcinomas,
histologic subtypes thought to have a different pathogene-
sis than the more common serous carcinomas, again sug-
gesting that claudin-4 overexpression may be present at
the earliest stages of tumorigenesis.
Overexpression of claudin-4 may be mediated through
multiple mechanisms, and gene amplification may be one of
these. However, comparative genomic hybridization analysis
of our oligonucleotide array did not show any changes in
CLDN4 DNA copy number (data not shown). Methylation of
5V-cytosines in CpG islands is one of the most important
epigenetic modulators of gene expression [39], and alter-
ations in the methylation status of CLDN4 and the CLDN7
promoter have been associated with aberrant gene expres-
sion in pancreatic and breast carcinomas, respectively
[13,21]. Using MSPCR, we found that all the ovarian cancer
cell lines with a hypomethylated CLDN4 allele overex-
pressed claudin-4 and that treatment with a demethylating
agent induced claudin-4 expression in cell lines not ex-
pressing claudin-4. Bilsufite sequencing was also per-
formed, and confirmed the completeness of the bisulfite
modification and the accuracy of the MSPCR results. Similar
findings were reported in an elegant and recently published
paper; namely, that promoter methylation and histone de-
acetylation contribute to claudin-4 silencing in ovarian cancer
cells [40]. As cultured cells may have an altered methylation
pattern compared to their tissue counterparts [13], we also
examined ovarian cancer tissue samples and found both
methylated and hypomethylated CLDN4 alleles in all the
samples (all of which overexpressed claudin-4). Although
the methylated PCR products in these tissue samples may
be secondary to stromal cell contaminants harvested at the
time of genomic DNA extraction, an alternative suggestion
is that CLDN4 was only partially hypomethylated. This view
is supported by Honda et al. [40], who showed that the
inhibition of claudin-4 expression is related to the density of
methylated CpG dinucleotides. Moreover, we observed both
methylated and unmethylated CLDN4 alleles in the cancer
cell lines OVCAR3 and OVCA432 and in the three HOSE
cell lines. In contrast to OVCAR3 and OVCA432, the three
HOSE cell lines did not express claudin-4. This observation
may again be related to the relative density of DNA methyla-
tion, as noted above. Alternatively, the above-mentioned
Figure 7. (A) Claudin-4 Western blot for SKOV3 WT, a negative control, and SKOV3 siRNA (claudin-4 silenced). -Actin was used as a loading control. (B)
Junctional (paracellular) resistance (Rb) was compared between SKOV3 WT (wild type) and SKOV3 siRNA (siRNA claudin-4 silenced) cell lines over 7 days in
cell culture medium, *P < .05. Cell lines (C) OVCA429 and (D) SKOV3 were treated with increasing amounts of C-CPE (g/l), resulting in a dose-dependent
decrease in Rb compared to control (cell culture medium only, C-CPE concentration of 0 g/l). Bars represent means ± SD. Measurements were repeated four to
six times, *P < .05.
312 Claudin-4–Targeted Tight Junction Modulation Litkouhi et al.
Neoplasia . Vol. 9, No. 4, 2007
authors also found that although claudin-4 expression in-
creased after treatment with inhibitors of DNA methylation
and histone deacetylase, the mRNA and protein products
did not correlate well. This suggests that other regulatory
mechanisms may be involved in the expression of claudin-4
[40]. Lastly, it is interesting to note that whereas Honda et al.
[40] characterized the methylation status of the CLDN4 pro-
moter as well as some downstream elements, our MSPCR
primers did not include the CLDN4 promoter region (Fig-
ure 6A); still, the methylation status of CLDN4 correlated
with claudin-4 expression.
Although other investigators have shown that claudin-4 is
overexpressed in ovarian cancer [3–7], the clinical and
biological significance of this finding is yet to be fully eluci-
dated. Claudin-4 overexpression has been associated with
platinum resistance in ovarian cancer based on proteomic
analysis [41], and moderate to strong claudin-4 staining was
associated with decreased survival in gastric carcinomas
[42]. Accordingly, we sought to compare claudin-4 expres-
sion to several clinically important outcomes. We found that
claudin-4 expression did not correlate with survival, nor
was expression different between primary and recurrent tu-
mors. Consistent with this finding, claudin-4 expression was
not different between chemoresistant and chemosensitive
tumors, and expression did not correlate with the ability to
optimally debulk tumor burden at the time of surgery. These
findings suggest that although claudin-4 overexpression may
have an important role in ovarian cancer, its overexpression
is not a marker of increased tumor aggressiveness per se.
Claudin proteins form the backbone of TJ strands [9], and
their existence is necessary and sufficient for TJ formation
[8]. Yet, although claudin-4 predominantly localizes to the cell
membrane in ovarian cancer, as shown in this study and by
others [3,4,7], it is not clear whether this corresponds to the
formation of functional TJs with the ability to regulate para-
cellular flow (barrier function). Although Zhu et al. [43]
suggested that functional TJs exist in normal ovarian surface
epithelium, using the transepithelial electric resistance (TER)
method, Rangel et al. [6] suggested that claudin-4 over-
expression in ovarian cancer does not correlate with the
presence of functional TJs. TER measurements have been
directly related to TJ barrier function [9]; however, TER data
can be inconsistent, do not always correlate with TJ mor-
phology, and do not separately account for the resistance
due to cell–substrate contacts [9,44]. With this in mind, we
used ECIS to measure TJ barrier function. ECIS accounts for
the transepithelial current flowing through the paracellular
and cell –substrate spaces separately and, as a result,
individually determines the contribution of each of these
currents to total transepithelial resistance [44]. Using ECIS,
we found that as claudin-4 expression increased, so did the
junctional (paracellular) resistance. Junctional resistance
was also found to be significantly lower in claudin-4 silenced
SKOV3 cells compared to the wild type. Lastly, treatment of
claudin-4–expressing ovarian cancer cell lines with a C-
terminal fragment of C. perfringens enterotoxin (C-CPE),
which binds claudin-4, resulted in decreased junctional re-
sistance in a dose- and claudin-4–dependent fashion, and
this was not due to cell cytotoxicity. These findings suggest
that claudin-4 contributes to the formation of functional TJs
and is consistent with the observation that epithelial ovarian
carcinomas, as opposed to most other cancers, acquire
more stable and more differentiated epithelial characteristics
and morphology as tumorigenesis proceeds [45].
Jang et al. [46] observed that pretreatment with pacli-
taxel decreased cell density and improved subsequent drug
penetration and accumulation in the tumor core. Accordingly,
the ability of cytotoxic drugs to diffuse paracellularly through
the interstitium deep into the tumor core may be important,
especially for IP drug delivery, when drugs are delivered
without primary access to the vascular compartment and
thus largely depend on surface diffusion [25]. C-CPE has
been used in a noncytotoxic manner to target claudin-4,
disrupt TJ barrier function, and hence improve drug delivery
in the small bowel [23]. Our demonstration that C-CPE de-
creased TJ barrier function (junctional resistance) in ovarian
cancer cells in a dose- and claudin-4–dependent fashion
raises the possibility that C-CPE may play a future role in
drug delivery strategies. C-CPE may potentially be used as
an absorption or diffusion-enhancing agent, or, alternatively,
by acting as a claudin-4–targeting fusion molecule [27].
Lastly, although claudins are known to localize exclusively
to the TJ [9], using ECIS, we also found that C-CPE affected
the cell–substrate separation (data not shown). Whether
this observation is due to mechanical alterations in the cell
cytoskeleton or changes in cell signaling secondary to TJ
disruption is a current area of investigation by our group.
In summary, our results confirm that claudin-4 is over-
expressed in a variety of EOCs and that this is related
to CLDN4 hypomethylation. Furthermore, claudin-4 over-
expression in EOC may be an early event and is not a
marker of increased tumor aggressiveness or poor progno-
sis. Lastly, it appears that claudin-4 overexpression cor-
responds with the existence of functional TJs, and that
C-CPE, which targets claudin-4, may be used to diminish
TJ barrier function. Future studies examining the biologic
response of ovarian cancer to C-CPE, alone and in combi-
nation with cytotoxic drugs, and studies using animal models
are currently under way to further evaluate and expand on
these findings.
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